Resverlogix Announces Company Update Webcast and Conference Call


CALGARY, Alberta, December 13, 2021 (GLOBE NEWSWIRE) – Resverlogix Corp. (“Resverlogix”) (TSX: RVX) announced today that it will host a corporate update webcast and conference call on Thursday, December 16e, 2021 at 2:00 p.m. MST.

Webcast link:

Conference Call Information:

Canada / United States TF: 1-800-319-4610
Toll Free from Toronto: + 1-416-915-3239

About Apabetalone

Apabetalone (RVX-208) is a first-in-class small molecule therapeutic candidate with an epigenetic mechanism of action. It is a selective BD2 (bromodomain) BET (bromodomain and extra-terminal) inhibitor that works to prevent and treat disease progression by regulating the expression of disease-causing genes. Due to the important role of BET proteins in the human body, apabetalone can simultaneously target several disease-related biological processes while maintaining a well-described safety profile, leading to a novel way of treating chronic disease. Apabetalone is the only drug in its class with a proven safety record in human clinical trials, with over 4,200 patient years on the drug in 10 clinical trials.


At March 23, 2020, Resverlogix launched its COVID-19 program, recruiting world-renowned collaborators. Studies show that apabetalone has the potential to work against COVID-19 with a unique dual mechanism: first, by preventing viruses from entering cells and replicating; and second, by avoiding excessive inflammatory reactions which can cause serious and lasting organ damage. A Phase 2 clinical trial is evaluating apabetalone in combination with standard care for hospital patients for COVID-19. The experimental treatment could potentially reduce the severity and duration of COVID-19. Apabetalone’s unique dual mechanism also means that it has the potential to show its effectiveness against newer variants of COVID-19 and may even help fight other viruses.

Resverlogix has partnered with EVERSANA ™, the pioneer of next-generation business services for the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. EVERSANA ™ is currently leading the clinical awareness and advocacy for apabetalone in the Canadian market.


In February 2020, apabetalone became the first such therapy to receive breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) – for a major cardiovascular indication – following groundbreaking results from the ‘BETonMACE phase three study. Data from BETonMACE have shown that apabetalone can potentially prevent major adverse cardiac events in patients with high-risk cardiovascular disease who also have type 2 diabetes.

About Resverlogix

Founded in 2001, Resverlogix is ​​a Calgary-based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing world-leading therapies for the benefit of patients with chronic disease.

Resverlogix markets a new class of epigenetic therapies designed to regulate the expression of pathogenic genes. We aim to improve the lives of patients by restoring biological functions – altered by serious illnesses such as cardiovascular disease – to a healthier state.

The Company’s clinical program is focused on the evaluation of the leading epigenetic candidate, apabetalone, for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Follow us: Twitter: @Resverlogix_RVX. LinkedIn:

Forward-looking statements:

This press release may contain certain forward-looking information as defined by applicable Canadian securities legislation, which is not based on historical fact, including, without limitation, statements containing the words “believes”, “Anticipates”, “plans”, “intends”, “” will “,” should “,” expects “,” continue “,” estimate “,” foresee “and other similar expressions. In particular, this press release includes forward-looking information relating to the Company’s Phase 2 clinical trial for the potential treatment of COVID-19 patients with apabetalone (and potentially other viruses), cardiovascular disease and associated comorbidities and other chronic diseases. Our actual results, events or developments could differ materially from those expressed or implied by these forward-looking statements. We cannot guarantee that any of the events or expectations will or will happen. By their nature, forward-looking statements are subject to many assumptions and risk factors, including those described in our Annual Information Form and the most recent MD&A which are incorporated herein by reference and are available on SEDAR at address The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or liability, except as required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Investor Relations
Email: [email protected]
Telephone: 403-254-9252

Main logo

Source link


Comments are closed.